A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
第3相
完了
NCT05523323
| 対象疾患 | Head and Neck Squamous Cell Carcinoma |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Merck Sharp & Dohme LLC |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 112 名 |
|---|
| 介入（薬剤） | Lenvatinib, Pembrolizumab |
|---|
| 開始日 | 2020年10月30日 |
|---|
| 完了日 | 2023年8月25日 |
|---|
| 結果公開日 | 2024年10月18日 |
|---|
概要
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR. * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Up to approximately 33 months · Percentage of participants
| Pembrolizumab + Lenvatinib | 39.3 Percentage of participants |
|---|
| Pembrolizumab + Placebo | 9.8 Percentage of participants |
|---|
| p-value | 0.0002014 |
|---|
| Estimate difference | 29.5 (95% CI 14.0–43.9) |
|---|
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Up to approximately 33 months · Months
| Pembrolizumab + Lenvatinib | 7.0 Months |
|---|
| Pembrolizumab + Placebo | 1.5 Months |
|---|
| p-value | 0.0000037 |
|---|
| Hazard Ratio (HR) | 0.34 (95% CI 0.21–0.55) |
|---|
Overall Survival (OS)
Up to approximately 33 months · Months
| Pembrolizumab + Lenvatinib | 10.9 Months |
|---|
| Pembrolizumab + Placebo | 11.9 Months |
|---|
| p-value | 0.30933 |
|---|
| Hazard Ratio (HR) | 0.86 (95% CI 0.49–1.54) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。